CELCUITY INC (CELC)
Health Care · clinical-stage oncology biotechnology · NASDAQ
Celcuity is developing gedatolisib, a comprehensive PI3K/AKT/mTOR pathway inhibitor in Phase 3 trials for hormone receptor-positive breast cancer and metastatic prostate cancer.
What CELCUITY INC does
Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor targeting the PI3K/AKT/mTOR pathway, which is currently being evaluated in Phase 3 clinical trials for hormone receptor-positive, HER2-negative advanced breast cancer and in Phase 1b/2 trials for metastatic castration-resistant prostate cancer.
Themes: ["oncology / solid tumors"]
Fundamentals
- Price$113.51 as of 2026-07-09 close
- Market cap$5.5B as of 2026-07-10
- 1-year return+740.2% as of 2026-07-09 close
- ROE-244.6% as of 2026-07-10
- Debt / equity6.04 as of 2026-07-10
- Beta0.19 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: gedatolisib is still in Phase 3 trials with no FDA approval yet; trial failure or delays could prevent commercialization and generate significant losses."]
Competitors & peers
- Roche (RHHBY) - PI3K and mTOR inhibitors
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.